TEL AVIV, ISRAEL / DE BILT, NETHERLANDS – Codivir, a short synthetic 16 amino-acid peptide, derived from the HIV-1 integrase, was originally discovered at the Hebrew University in Israel. Code Pharma discovered that the peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus causing COVID-19. In-vitro studies conducted at the British virology research laboratory Virology Research Services in London then demonstrated a potent antiviral activity against SARS-CoV-2 and other RNA viruses. Subsequently, a phase I clinical trial of Codivir in patients with COVID-19 was approved in Brazil by the National Research Ethics Commission (CONEP). The trial was conducted at
The post Codivir Shows Promising Effect Against COVID-19 appeared first on Pharma Mirror Magazine.
